tetano
Editor, Senior Moderator
Virology
. 2021 Feb 1;558:28-37.
doi: 10.1016/j.virol.2021.01.003. Online ahead of print.
Development of a SARS-CoV-2 nucleocapsid specific monoclonal antibody
James S Terry[SUP] 1 [/SUP], Loran Br Anderson[SUP] 1 [/SUP], Michael S Scherman[SUP] 1 [/SUP], Carley E McAlister[SUP] 2 [/SUP], Rushika Perera[SUP] 2 [/SUP], Tony Schountz[SUP] 2 [/SUP], Brian J Geiss[SUP] 3 [/SUP]
Affiliations
Abstract
To help fight COVID-19, new molecular tools specifically targeting critical components of the causative agent of COVID-19, SARS-Coronavirus-2 (SARS-CoV-2), are desperately needed. The SARS-CoV-2 nucleocapsid protein is critical for viral replication, integral to viral particle assembly, and a major diagnostic marker for infection and immune protection. Currently the limited available antibody reagents targeting the nucleocapsid protein are not specific to SARS-CoV-2 nucleocapsid protein, and sequences for these antibodies are not publicly available. In this work we developed and characterized a series of new mouse monoclonal antibodies against the SARS-CoV-2 nucleocapsid protein, with a specific clone, mBG86, targeting only SARS-CoV-2 nucleocapsid protein. The monoclonal antibodies were validated in ELISA, Western blot, and immunofluorescence analyses. The variable regions from six select clones were cloned and sequenced, and preliminary epitope mapping of the sequenced clones was performed. Overall, these new antibody reagents will be of significant value in the fight against COVID-19.
. 2021 Feb 1;558:28-37.
doi: 10.1016/j.virol.2021.01.003. Online ahead of print.
Development of a SARS-CoV-2 nucleocapsid specific monoclonal antibody
James S Terry[SUP] 1 [/SUP], Loran Br Anderson[SUP] 1 [/SUP], Michael S Scherman[SUP] 1 [/SUP], Carley E McAlister[SUP] 2 [/SUP], Rushika Perera[SUP] 2 [/SUP], Tony Schountz[SUP] 2 [/SUP], Brian J Geiss[SUP] 3 [/SUP]
Affiliations
- PMID: 33714753
- DOI: 10.1016/j.virol.2021.01.003
Abstract
To help fight COVID-19, new molecular tools specifically targeting critical components of the causative agent of COVID-19, SARS-Coronavirus-2 (SARS-CoV-2), are desperately needed. The SARS-CoV-2 nucleocapsid protein is critical for viral replication, integral to viral particle assembly, and a major diagnostic marker for infection and immune protection. Currently the limited available antibody reagents targeting the nucleocapsid protein are not specific to SARS-CoV-2 nucleocapsid protein, and sequences for these antibodies are not publicly available. In this work we developed and characterized a series of new mouse monoclonal antibodies against the SARS-CoV-2 nucleocapsid protein, with a specific clone, mBG86, targeting only SARS-CoV-2 nucleocapsid protein. The monoclonal antibodies were validated in ELISA, Western blot, and immunofluorescence analyses. The variable regions from six select clones were cloned and sequenced, and preliminary epitope mapping of the sequenced clones was performed. Overall, these new antibody reagents will be of significant value in the fight against COVID-19.